Summary
Adverse reactions to practolol were studied in 198 prospectively monitored hospitalized medical patients. The mean age of the practolol recipients was 57 years; angina and cardiac arrhythmias were the most common indications for therapy. Adverse reactions were attributed to practolol in 20 patients (10%). Fifteen of these twenty reactions involved impairment of cardiac function (bradyarrhythmias, heart block, congestive heart failure, hypotension), and in three instances the reaction was considered life-threatening. Three additional patients had cutaneous reactions attributed to the drug. Adverse reactions to practolol were not dose-related, but toxicity appeared to be more frequent among patients concurrently receiving quinidine. The frequency of cardiovascular complications of propranolol in a similar series of patients was nearly identical. However, no skin reactions were attributed to propranolol. The findings suggest that practolol and propranolol produce unwanted cardiovascular effects with nearly equal frequency among hospitalized patients. Cutaneous reactions to practolol are evident even during short-term use.
Similar content being viewed by others
References
Arndt, K.A., Jick, H.: Rates of cutaneous reactions to drugs: a report from the Boston Collaborative Drug Surveillance Program. J. Amer. Med. Ass.235, 918–923 (1976)
Barrett, A.M.: The pharmacology of practolol. Postgrad. Med. J.47 (Suppl), 7–12 (Jan, 1971)
Brown, P., Baddeley, H., Read, A.E., Davies, J.D., McGarry, J.: Sclerosing peritonitis, an unusual reaction to a β-adrenergic blocking drug (practolol). Lancet1974 II, 1477–1481
Dunlop, D., and Shanks, R.G.: Selective blockade of adrenoceptive beta receptors in the heart. Brit. J. Pharmacol.32, 201–218 (1968)
Feliz, R.H., Ive, F.A., Dahl, M.G.C.: Cutaneous and ocular reactions to practolol. Brit. Med. J.1974/4, 321–324
Goldstein, R.E.: A comparison of beta-blocking agents. Circulation47, 443–445 (1973)
Goldstein, R.E., Hall, R.A., Epstein, S.E.: Comparison of relative inotropic and chronotropic effects of propranolol, practolol, and sotalol. Chest64, 619–627 (1973)
Greenblatt, D.J., Koch-Weser, J.: Adverse reactions to propranolol in hospitalized medical patients: a report from the Boston Collaborative Drug Surveillance Program. Amer. Heart J.86, 478–484 (1973)
Greenblatt, D.J., Koch-Weser, J.: Adverse reactions to β-adrenergic receptor blocking drugs: a report from the Boston Collaborative Drug Surveillance Program. Drugs7, 118–129 (1974)
Improvement in prognosis of myocardial infarction by long-term use of beta-adrenoceptor blockade using practolol: a multicentre international study. Brit. Med. J.1975/3, 735–740
Jensen, H.E., Mikkelsen, H.I., Wadskov, S., Sondergaard, J.: Cutaneous reactions to propranolol (Inderal). Acta Med. Scand.199, 363 (1976)
Jick, H.: Drugs-remarkably nontoxic. New Engl. J. Med.291, 824–828 (1974)
Liang, C.-S., Hood, W.B.: The myocardial depressant effect of beta-receptor blocking agents. Circulat. Res.35, 272–280 (1974)
Miller, R.R.: Drug surveillance utilizing epidemiologic methods: a report from the Boston Collaborative Drug Surveillance Program. Amer. J. Hosp. Pharm.30, 584–592 (1973)
Miller, R.R., Greenblatt, D.J.: Drug Effects in Hospitalized Patients: Experiences of the Boston Collaborative Drug Surveillance Program, 1966–1975. New York: John Wiley and Sons 1976
Raftery, E.B., Denman, A.M.: Systemic lupus erythematosus syndrome induced by practolol. Brit. Med. J.1973/2, 252–255
Waal-Manning, H.J.: Problems with practolol. Drugs10, 336–341 (1975)
Wright, P.: Untoward effects associated with practolol administration: oculomucocutaneous syndrome. Brit. Med. J.1975/1, 595–598
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pfeifer, H.J., Greenblatt, D.J. & Koch-Weser, J. Adverse reactions to practolol in hospitalized patients. Eur J Clin Pharmacol 12, 167–170 (1977). https://doi.org/10.1007/BF00609854
Issue Date:
DOI: https://doi.org/10.1007/BF00609854